PTC Therapeutics Rallies 18% on EU Authorization Update for Translarna
Express News | Edgewise Therapeutics Inc : JP Morgan Raises Target Price to $27 From $24
Edgewise Therapeutics Inc (EWTX) Reports First Quarter 2024 Financial Results
Edgewise Therapeutics' New $175M Stock Sale Agreement and Previous Termination
Express News | Edgewise Therapeutics - Sales Agreement Prospectus Covering Offering of up to $175 Mln of Common Stock That May Be Issued Under Sales Agreement
Express News | Edgewise Therapeutics Files for Mixed Shelf Offering, Size Not Disclosed - Filing
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024
Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15,
Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating
Edgewise Therapeutics (EWTX) has an average rating of buy and price targets ranging from $24 to $48, according to analysts polled by Capital IQ. Price: 19.52, Change: -0.48, Percent Change: -2.40
HHS Panel to Vote in Nov. on DMD Screening for Newborns
Express News | Edgewise Therapeutics - Expects to Report Data From Single Dose Arm of Cirrus-HCM and Phase 1 Trial of Edg-7500 in Healthy Volunteers in Q3 of 2024
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
As of May 9, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator,
Express News | Edgewise Therapeutics Inc: Positive Interim Topline Data for Dune Trial of Sevasemten in Becker
Express News | Edgewise Therapeutics Inc: Expanded Phase 2 Lynx Trial of Sevasemten in Duchenne
Express News | Edgewise Therapeutics Inc: –Initiated Phase 2 Cirrus-HCM Trial of Edg-7500 in Patients With Obstructive HCM
Edgewise Therapeutics | 10-Q: Quarterly report
Express News | Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Express News | Edgewise Therapeutics Q1 Operating Expenses USD 34.753 Million
Express News | Edgewise Therapeutics Q1 Basic EPS USD -0.33
Express News | Edgewise Therapeutics Q1 Net Income USD -28.525 Million
Edgewise Therapeutics's EDG-7500: A Promising Contender in HCM Treatment Landscape